When was Entos Pharmaceuticals founded?

Entos Pharmaceuticals was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Entos Pharmaceuticals located?

Entos Pharmaceuticals is headquartered in Edmonton, Canada.

Who is the current CEO of Entos Pharmaceuticals?

John Lewis of Entos Pharmaceuticals.

How many employees does Entos Pharmaceuticals have?

As of Aug 31, 2026, the latest employee count at Entos Pharmaceuticals is 33.

Is Entos Pharmaceuticals a funded company?

Entos Pharmaceuticals is a funded company, having raised a total of $1.1M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 26, 2020.

When was the latest funding round of Entos Pharmaceuticals?

Entos Pharmaceuticals' latest funding was a $***** Series A round on May 22, 2025, with participation from 1 investor.

Where does Entos Pharmaceuticals rank among its competitors?

Entos Pharmaceuticals ranks 204th amongst 2806 active competitors, of which 748 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Entos Pharmaceuticals?

Entos Pharmaceuticals' top competitors include Alnylam, Spark Therapeutics and Senti Bio. Among them, Senti Bio secured the most recent funding round in May, 2026.

Entos Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Entos Pharmaceuticals is a series A company based in Edmonton (Canada), founded in 2016. It operates as a Provider of nanotech-based drug delivery solutions. Entos Pharmaceuticals has raised $1.1M in funding. The company has 2806 active competitors, including 748 funded and 486 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Senti Bio.

Company Details

Provider of nanotech-based drug delivery solutions. The company is focused on the development of next-generation nucleic acid-based therapies using their proprietary drug delivery system. The system uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, and CRISPR.

Key Metrics

Founded Year

2016

Location

Edmonton, Canada

Stage

Series A

Total Funding

$1.1M in 4 rounds

Latest Funding Round

Series A, May 22, 2025, $*****

Investors

Tao Capital Partners & 4 more

Ranked

204^th among 2806 active competitors

Employee Count

33 as on Aug 31, 2026

Similar Companies

Alnylam & 3705 more

View Entos Pharmaceuticals' full profile

Entos Pharmaceuticals has raised a total funding of $1.1M over 4 rounds. Its first funding round was on May 26, 2020. Its latest funding round was a Series A round on May 22, 2025 for $*****. 1 investor participated in its latest round. Entos Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of Entos Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 22, 2025	9987212	Series A	1005569	3247983	3989082	6279524
Feb 05, 2025	2785449	Grant (prize money)	7679374	1837494	2429339	State of California
Oct 23, 2020	6335358	Grant (prize money)	5057405	9605607	5335478	Canadian Space Agency

Access funding benchmarks and valuations. Sign up today!

View details of Entos Pharmaceuticals's funding rounds and investors

Entos Pharmaceuticals' employee count trend

Entos Pharmaceuticals has 33 employees as of Aug 26. Here is Entos Pharmaceuticals's employee count trend over the years:

Employee count trend for Entos Pharmaceuticals

Uncover Entos Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Entos Pharmaceuticals include Alnylam, Spark Therapeutics and Senti Bio. Here is the list of Top 10 competitors of Entos Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
5th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, RA Capital Management & 7 others	70/100
8th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	69/100
204th	Entos Pharmaceuticals 2016, Edmonton (Canada), Series A	Provider of nanotech-based drug delivery solutions	$1.1M	Tao Capital Partners, State of California ... & 3 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Entos Pharmaceuticals's competitors? Click here to see the top ones

Entos Pharmaceuticals has made no investments or acquisitions yet.

Media has covered Entos Pharmaceuticals for a total of 3 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.